View More Recent Stories
-
Beam Therapeutics Inc. (BEAM) Appoints Sravan Emany as CFO
-
Beam Therapeutics (BEAM) Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
-
Leerink Partners Upgrades Beam Therapeutics Inc (BEAM) to Outperform, 'we see a far more attractive risk/reward'
-
JPMorgan Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)
-
Stifel Defending Beam Therapeutics Inc (BEAM): 'Reactions To Initial BEAM-101 Update Strikes Us As Overreaction'
-
BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'
-
Beam, Inc. (BEAM) Tops Q3 EPS by 1c
-
Jones Trading Starts Beam Therapeutics Inc (BEAM) at Hold
-
Beam Therapeutics Inc (BEAM) PT Raised to $69 at Stifel
-
Beam, Inc. (BEAM) Tops Q2 EPS by 2c
-
Beam Therapeutics Inc. (BEAM) Announces CFO Change

